Nature Biotechnology’s annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with microbiome treatments or immunotherapy. Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel and Laura DeFrancesco report.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M., Garber, K., Landhuis, E. et al. Nature Biotechnology’s academic spinouts 2020. Nat Biotechnol 39, 1036–1047 (2021). https://doi.org/10.1038/s41587-021-01043-x
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-021-01043-x
